Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials
- 1 January 2008
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 371 (9606), 29-40
- https://doi.org/10.1016/s0140-6736(08)60069-0
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Effects of Estrogen Receptor Expression and Histopathology on Annual Hazard Rates of Death from Breast CancerBreast Cancer Research and Treatment, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Influence of Endocrine-Related Factors on Response to Perioperative Chemotherapy for Patients With Node-Negative Breast CancerJournal of Clinical Oncology, 2001
- Subsets within the chemotherapy overviewThe Lancet, 1998
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer.Journal of Clinical Oncology, 1997
- Prolonged Disease-Free Survival after One Course of Perioperative Adjuvant Chemotherapy for Node-Negative Breast CancerThe New England Journal of Medicine, 1989
- Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in advanced breast cancerCancer, 1981
- Estrogen Receptors and Responses to Chemotherapy and Hormonal Therapy in Advanced Breast CancerThe New England Journal of Medicine, 1978
- The Relation between Estrogen Receptors and Response Rate to Cytotoxic Chemotherapy in Metastatic Breast CancerThe New England Journal of Medicine, 1978